TregTherapeutics, Inc. was established to commercialize a game-changing technology that potentially satisfies the quest for stopping the devastating consequences of autoimmune disease. To expedite this process our initial objective is to advance the technology into human proof-of-concept studies sufficient to attract disease-specific development partners with manufacturing and marketing expertise. Our team, consisting of a lean direct staff and a balanced consulting/advisory council with diverse technical and managerial experience in leading execution of preclinical development plans and a Phase 1/2a clinical study in plaque psoriasis. The virtual nature of our organization is designed to take advantage of the wide-ranging resources available through remote communication and the existence of committed, experienced academic clinical research partners, as well as, operational prowess of contract research organizations (CROs). Efficiency and prudent financial management characterize operations. Upon successful completion of the Phase 1/2a study we will actively seek pharmaceutical company development partners who possess the resources and expertise to move the therapy through the latter stages of development both in Plaque Psoriasis and other autoimmune diseases.